| Budget Amount *help |
¥33,540,000 (Direct Cost: ¥25,800,000、Indirect Cost: ¥7,740,000)
Fiscal Year 2014: ¥10,660,000 (Direct Cost: ¥8,200,000、Indirect Cost: ¥2,460,000)
Fiscal Year 2013: ¥11,180,000 (Direct Cost: ¥8,600,000、Indirect Cost: ¥2,580,000)
Fiscal Year 2012: ¥11,700,000 (Direct Cost: ¥9,000,000、Indirect Cost: ¥2,700,000)
|
|---|
| Outline of Final Research Achievements |
1. Fusicoccin A is a diterpene glucoside produced by the fungus Phomopsis amygdali and its derivative lacking the OH group at the 12-position is revealed to be a potential anti-cancer drug. We therefore constructed a mutant producing the desirable intermediate by biosynthetic engineering. 2. Three fungal prenyltransferases, PaxC, PaxD, and AtmD, all of which are responsible for biosynthesis of indole diterpene compounds, were characterized. 3. Aminodeoxyfutalosine is the first intermediate in the new menaquinone biosynthetic pathway. We demonstrated that a radical S-adenosyl methionine enzyme (MqnE) catalyzed the addition of the adenosyl radical to the double bond of 3-[(1-carboxyvinyl)oxy]benzoic acid derived from chorismate by MqnA. 4. During the biosynthetic studies of pheganomycin, we identified a new ATP-grasp enzyme, which phosphorylated the non-proteogenic amino acids with ATP and the successive nucleophilic attack of the peptides.
|
